|
127 Companies |
|
123 Products |
|
123 Products |
|
59 Mechanisms of Action |
|
6 Trials |
|
3245 News |
|
| «12...4849505152535455565758...6566» |
- Trial termination: Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant (clinicaltrials.gov) - Mar 13, 2013
P3, N=240, Terminated, Sponsor: OHSU Knight Cancer Institute
Active, not recruiting --> Terminated
- | Vaxigrip (inactivated influenza vaccine (split virion)) / Sanofi
New P4 trial: Effect of HIV and/or Active Tuberculosis on the Immune Responses to Trivalent Influenza Vaccine (TIV) in Adults (clinicaltrials.gov) - Mar 13, 2013
P4, N=360, Not yet recruiting, Sponsor: University of Witwatersrand, South Africa
- |||| PF-06290510 / Pfizer
Trial completion: Evaluation of a Single Vaccination With One of Three Ascending Dose Levels of a 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) in Healthy Adults Aged 18 to <65 Years (clinicaltrials.gov) - Mar 11, 2013
P1/2, N=456, Completed, Sponsor: Pfizer
Active, not recruiting --> Terminated Active, not recruiting --> Completed
- Trial completion: Incidence of Bacteremia Following Argon Plasma Coagulation in Patients With Endobronchial Lesions (clinicaltrials.gov) - Mar 11, 2013
P=N/A, N=46, Completed, Sponsor: Meir Medical Center
Active, not recruiting --> Completed Recruiting --> Completed
- pretomanid (PA-824) / Global Alliance for TB Drug Development
Enrollment closed: Evaluation of 8 Weeks of Treatment With the Combination of Moxifloxacin, PA-824 and Pyrazinamide in Patients With Drug Sensitive and Multi Drug-Resistant Pulmonary Tuberculosis (TB) (NC-002) (clinicaltrials.gov) - Mar 11, 2013
P2, N=230, Active, not recruiting, Sponsor: Global Alliance for TB Drug Development
Recruiting --> Completed Recruiting --> Active, not recruiting
- Trial withdrawal: Clinical Evaluation of the APTIMA® Assay for Chlamydia Trachomatis Using the PANTHER™ System (clinicaltrials.gov) - Mar 7, 2013
P=N/A, N=0, Withdrawn, Sponsor: Gen-Probe, Incorporated
Recruiting --> Active, not recruiting Completed --> Withdrawn
- Enrollment change: Clinical Evaluation of the APTIMA® Assay for Chlamydia Trachomatis Using the PANTHER™ System (clinicaltrials.gov) - Mar 7, 2013
P=N/A, N=0, Withdrawn, Sponsor: Gen-Probe, Incorporated
Completed --> Withdrawn N=1351 --> 0
- ||||| levofloxacin / Generic mfg.
Trial initiation date: A Study of Incidence of Musculoskeletal Disorders in Children Who Have Received Levofloxacin or a Standard Non-Fluoroquinolone Therapy for Acute Bacterial Infection (clinicaltrials.gov) - Mar 7, 2013
P3, N=2233, Completed, Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
N=1351 --> 0 Initiation date: Feb 2002 --> Aug 2002
- | Enrollment change: Early Antiretroviral Treatment and/or Early Isoniazid Prophylaxis Against Tuberculosis in HIV-infected Adults (ANRS 12136 TEMPRANO) (clinicaltrials.gov) - Mar 7, 2013
P3, N=2073, Active, not recruiting, Sponsor: French National Agency for Research on AIDS and Viral Hepatitis
Initiation date: Feb 2002 --> Aug 2002 N=1642 --> 2073
- ||||||| Xepi (ozenoxacin) / Maruho, Cipher, Ferrer International
Trial completion: Efficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With Impetigo (clinicaltrials.gov) - Mar 5, 2013
P3, N=465, Completed, Sponsor: Ferrer Internacional S.A.
N=1642 --> 2073 Recruiting --> Completed
- Trial termination: Utility of MODS for Diagnosis of MDR-TB and Second-Line Antituberculous Drug Susceptibility Testing in Mali (clinicaltrials.gov) - Mar 5, 2013
P=N/A, N=340, Terminated, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Completed Recruiting --> Terminated
- |||| Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD), Vaxneuvance (15-valent pneumococcal conjugate vaccine) / Merck (MSD)
Trial completion: The Safety, Tolerability, and Immunogenicity Profiles of a Single Dose of V114, PNEUMOVAX® 23, or PREVNAR 13® in Adults 50 Years of Age or Older (V114-002) (clinicaltrials.gov) - Mar 4, 2013
P2, N=692, Completed, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Terminated Active, not recruiting --> Completed
- Trial completion: The Role of Routine Bacterial Culture Including Tuberculosis During Bronchoscopy: A Prospective Study (clinicaltrials.gov) - Mar 4, 2013
P=N/A, N=300, Completed, Sponsor: Meir Medical Center
Active, not recruiting --> Completed Recruiting --> Completed
- | New P2 trial: Quadruple Therapy Versus Dual Therapy as Rescue Regimens for Helicobacter Pylori Infection (clinicaltrials.gov) - Mar 4, 2013
P2, N=114, Completed, Sponsor: Shanghai Jiao Tong University School of Medicine
- Enrollment change: Conversion Rate of (TST) Tuberculin Skin Test and Quantiferon-TB Gold In Tube Assay in Health Care Workers (clinicaltrials.gov) - Mar 3, 2013
P=N/A, N=53, Completed, Sponsor: Yonsei University
Recruiting --> Completed N=120 --> 53
- Enrollment open: Evaluation in the Treatment of Nosocomial Sepsis Comparing Polymerase Chain Reaction With Conventional Blood Culture. (clinicaltrials.gov) - Mar 3, 2013
P4, N=200, Recruiting, Sponsor: Instituto do Coracao
N=120 --> 53 Not yet recruiting --> Recruiting
- Trial completion: Conversion Rate of (TST) Tuberculin Skin Test and Quantiferon-TB Gold In Tube Assay in Health Care Workers (clinicaltrials.gov) - Mar 3, 2013
P=N/A, N=53, Completed, Sponsor: Yonsei University
Not yet recruiting --> Recruiting Recruiting --> Completed
- ||||| Lytixar (LTX-109) / Lytix
New P2 trial: A Phase II Study to Evaluate the Efficacy and Safety of Two Doses of LTX-109 in Impetigo (clinicaltrials.gov) - Feb 28, 2013
P2, N=210, Completed, Sponsor: Lytix Biopharma AS
- Clinical: Characterizing and Comparing the Profile of Microorganisms From Specific Body Sites and Environmental Surfaces in Newly Disinfected Patient Rooms (clinicaltrials.gov) - Feb 28, 2013
P=N/A, N=80, Recruiting, Sponsor: Duke University
- | lanopepden (GSK1322322) / GSK
New P1 trial: A Study to Evaluate the Effect of GSK1322322 on Cardiac Conduction as Assessed by 12-lead Electrocardiogram in Healthy Volunteers (clinicaltrials.gov) - Feb 28, 2013
P1, N=40, Not yet recruiting, Sponsor: GlaxoSmithKline
- rifampicin / Generic mfg.
New P2 trial: Rifampicin Explorative PK Study for Tuberculous Meningitis Comparing Oral and Intravenous Preparation (clinicaltrials.gov) - Feb 27, 2013
P2, N=30, Active, not recruiting, Sponsor: Universitas Padjadjaran
- ||| Trial completion: To Evaluate the Incidence of Acute Otitis Media in Children in Five East European Countries (clinicaltrials.gov) - Feb 27, 2013
P=N/A, N=2258, Completed, Sponsor: GlaxoSmithKline
Recruiting --> Completed Recruiting --> Completed
- | clindamycin phosphate / Generic mfg.
New P4 trial: Clindamycin to Reduce Preterm Birth in a Low Resource Setting (clinicaltrials.gov) - Feb 26, 2013
P4, N=1726, Recruiting, Sponsor: Christiana Care Health Services
- || azithromycin / Generic mfg.
New P3 trial: PregnAnZI: Prevention of Bacterial Infections in Newborn (clinicaltrials.gov) - Feb 26, 2013
P3, N=830, Recruiting, Sponsor: Medical Research Council Unit, The Gambia
- Trial completion, IO biomarker: Toll-like Receptor 2 Gene Polymorphism, Serum Cytokines and Susceptibility to Disease Severity or Treatment Response of Pulmonary Tuberculosis (clinicaltrials.gov) - Feb 26, 2013
P=N/A, N=300, Completed, Sponsor: Chang Gung Memorial Hospital
Recruiting --> Completed Recruiting --> Completed
- Enrollment change: Latent Tuberculosis Infection in Bone Marrow Transplant Recipients (clinicaltrials.gov) - Feb 25, 2013
P=N/A, N=409, Completed, Sponsor: Asan Medical Center
Recruiting --> Completed N=235 --> 409
- |||||||||| amikacin inhalation solution (NKTR-061) / Nektar Therap
New P3 trial, Gram negative: Inhaled Amikacin Solution (BAY 41-6551) as Adjunctive Therapy in the Treatment of Gram-Negative Pneumonia (clinicaltrials.gov) - Feb 25, 2013
P3, N=650, Recruiting, Sponsor: Bayer
- Trial completion: A Study of MVA85A in Healthy Infants (clinicaltrials.gov) - Feb 24, 2013
P2, N=2797, Completed, Sponsor: Aeras
N=235 --> 409 Active, not recruiting --> Completed
- Trial withdrawal: Study Evaluating Tigecycline Versus Ceftriaxone In Complicated Intra-Abdominal Infections & Community Acquired Pneumonia (clinicaltrials.gov) - Feb 20, 2013
P3, N=0, Withdrawn, Sponsor: Pfizer
Active, not recruiting --> Completed Active, not recruiting --> Withdrawn
- Enrollment change: Study Evaluating Tigecycline Versus Ceftriaxone In Complicated Intra-Abdominal Infections & Community Acquired Pneumonia (clinicaltrials.gov) - Feb 20, 2013
P3, N=0, Withdrawn, Sponsor: Pfizer
Active, not recruiting --> Withdrawn N=300 --> 0
- Zeftera (ceftobiprole) / Basilea
Enrollment change: Ceftobiprole in the Treatment of Hospitalized Patients With Staphylococcus Aureus Bacteremia (clinicaltrials.gov) - Feb 18, 2013
P2, N=0, Withdrawn, Sponsor: Basilea Pharmaceutica
N=300 --> 0 N=45 --> 0
- | New P2 trial, Surgery: Validity Study of Glutamine to Improve Cardiac Function in Cardiac Surgery (clinicaltrials.gov) - Feb 18, 2013
P2, N=60, Recruiting, Sponsor: Yuejiang Liu
- MenAfriVac (meningococcal A conjugate vaccine) / Serum Institute of India
Trial withdrawal: A Case-control Study of the Efficacy of a New Serogroup A Meningococcal Conjugate Vaccine (MenAfriVac) in Mali and Niger (clinicaltrials.gov) - Feb 17, 2013
P=N/A, N=0, Withdrawn, Sponsor: London School of Hygiene and Tropical Medicine
N=45 --> 0 Recruiting --> Withdrawn
- MenAfriVac (meningococcal A conjugate vaccine) / Serum Institute of India
Enrollment change: A Case-control Study of the Efficacy of a New Serogroup A Meningococcal Conjugate Vaccine (MenAfriVac) in Mali and Niger (clinicaltrials.gov) - Feb 17, 2013
P=N/A, N=0, Withdrawn, Sponsor: London School of Hygiene and Tropical Medicine
Recruiting --> Withdrawn N=800 --> 0
- | Trial completion: To Determine the Safety and Immunogenicity of an Oral(Whole Cell) Euvichol Cholera Vaccine in Healthy Adult Men (clinicaltrials.gov) - Feb 17, 2013
P1, N=20, Completed, Sponsor: EuBiologics Co.,Ltd
N=800 --> 0 Recruiting --> Completed
- Trial initiation date: An Open Cohort of Childhood Tuberculosis in Mbarara National Referral Hospital, Uganda (clinicaltrials.gov) - Feb 15, 2013
P=N/A, N=300, Recruiting, Sponsor: Epicentre
Recruiting --> Completed Initiation date: Oct 2011 --> Apr 2012
- Enrollment open: Impact of Specific Antimicrobials and MIC Values on the Outcome of Bloodstream Infections Due to Extended-spectrum Beta-lactamase (ESBL) or Carbapenemase-producing Enterobacteriaceae: an Observational Multinational Study (clinicaltrials.gov) - Feb 15, 2013
P=N/A, N=2000, Recruiting, Sponsor: JESUS RODRIGUEZ BAÑO
Initiation date: Oct 2011 --> Apr 2012 Not yet recruiting --> Recruiting
- Enrollment open: Screening of Children in Household Contact With Adult TB Patients in Mbarara Hospital, Uganda (clinicaltrials.gov) - Feb 15, 2013
P=N/A, N=288, Recruiting, Sponsor: Epicentre
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Enrollment open: An Open Cohort of Childhood Tuberculosis in Mbarara National Referral Hospital, Uganda (clinicaltrials.gov) - Feb 15, 2013
P=N/A, N=300, Recruiting, Sponsor: Epicentre
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Trial initiation date: NRA RETA: Evaluation Of The Performance Of The Nitrate Reductase And Resazurin Titre Assay For The Detection of Mycobacterium Tuberculosis Complex From Sputum In A High Tb and Hiv Setting (clinicaltrials.gov) - Feb 15, 2013
P=N/A, N=600, Completed, Sponsor: Epicentre
Not yet recruiting --> Recruiting Initiation date: Feb 2010 --> Sep 2011
- Trial completion: NRA RETA: Evaluation Of The Performance Of The Nitrate Reductase And Resazurin Titre Assay For The Detection of Mycobacterium Tuberculosis Complex From Sputum In A High Tb and Hiv Setting (clinicaltrials.gov) - Feb 15, 2013
P=N/A, N=600, Completed, Sponsor: Epicentre
Initiation date: Feb 2010 --> Sep 2011 Active, not recruiting --> Completed
- azithromycin / Generic mfg.
Enrollment open: A Surveillance and Azithromycin Treatment for Newcomers and Travelers Evaluation: The ASANTE Trial (clinicaltrials.gov) - Feb 14, 2013
P4, N=52, Recruiting, Sponsor: Johns Hopkins University
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- trimethoprim/sulfamethoxazole / Generic mfg., doxycycline / Generic mfg., mupirocin / Generic mfg.
Enrollment change: Comprehensive Strategy to Decolonize Methicillin-resistant Staphylococcus Aureus (MRSA) in the Outpatient Setting (clinicaltrials.gov) - Feb 13, 2013
P=N/A, N=15, Completed, Sponsor: Joseph Kim
Not yet recruiting --> Recruiting N=96 --> 15
- ||||||| Menactra (Meningococcal-groups A, C, Y and W-135 polysaccharide diphtheria toxoid conjugate vaccine) / Sanofi
Trial completion: Study of a Single Dose of Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine (SP284) in Japanese Subjects (clinicaltrials.gov) - Feb 13, 2013
P3, N=200, Completed, Sponsor: Sanofi Pasteur, a Sanofi Company
N=96 --> 15 Active, not recruiting --> Completed
- trimethoprim/sulfamethoxazole / Generic mfg., doxycycline / Generic mfg., mupirocin / Generic mfg.
Trial completion: Comprehensive Strategy to Decolonize Methicillin-resistant Staphylococcus Aureus (MRSA) in the Outpatient Setting (clinicaltrials.gov) - Feb 13, 2013
P=N/A, N=15, Completed, Sponsor: Joseph Kim
Active, not recruiting --> Completed Recruiting --> Completed
- Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
Trial completion: Humoral Determinants of Immunity to Pneumococcal Infection (clinicaltrials.gov) - Feb 13, 2013
P4, N=114, Completed, Sponsor: Daniel M. Musher MD
Recruiting --> Completed Recruiting --> Completed
- Trial completion: Response of Clostridium Difficile Infection to Metronidazole Therapy (clinicaltrials.gov) - Feb 13, 2013
P=N/A, N=290, Completed, Sponsor: VA Medical Center, Houston
Recruiting --> Completed Recruiting --> Completed
- | Enrollment change: Vancomycin vs. Nitazoxanide to Treat Recurrent C. Difficile Colitis (clinicaltrials.gov) - Feb 13, 2013
P3, N=52, Completed, Sponsor: VA Medical Center, Houston
Recruiting --> Completed N=100 --> 52
- | New P4 trial: Long-term Follow up Helicobacter Pylori Reinfection Rate After Second-Line Treatment: Bismuth-Containing Quadruple Therapy Versus Moxifloxacin-Based Triple Therapy (clinicaltrials.gov) - Feb 13, 2013
P4, N=648, Completed, Sponsor: Seoul National University Bundang Hospital
- pretomanid (PA-824) / Global Alliance for TB Drug Development
Trial completion: Effect of PA-824 and of PA-824 Plus Moxifloxacin on the QTc Interval in Healthy Volunteers (clinicaltrials.gov) - Feb 13, 2013
P1, N=74, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
N=100 --> 52 Recruiting --> Completed